Mavenclad (Cladribine Tablets) Data in Multiple Sclerosis Journal Show an Even Greater Treatment Effect in Patients With Highly Active Multiple Sclerosis
Darmstadt, Germany (ots/PRNewswire) - - Post-hoc analysis from the 2-year CLARITY study demonstrated that Mavenclad reduced the risk of 6-month EDSS progression by 47% vs placebo - Patients with highly active multiple sclerosis had an even greater treatment effect, reducing the risk by 82% vs placebo Merck, a ...
mehr